Riskpilot← Back to searchSign inGet full accessAktiebolaget Immuno
ABActiveOrg 5560566456Uddevallagatan 1General medical practice activities · NACE 8621Est. 19520 employees
Revenue 2024
SEK 640K
-19% vs 2023
EBITDA margin
10.9%
+4% vs 2023
Equity ratio
16.4%
Financial strength
Net profit 2024
SEK 166K
+61% vs 2023
| Revenue | SEK 640K | -19% |
| EBITDA | SEK 70K | +4% |
| Net profit | SEK 166K | +61% |
| Total assets | SEK 4,1M | +3% |
| Equity | SEK 674K | +33% |
| Employees | 0 | — |
Legal name
Aktiebolaget Immuno
Org number
5560566456
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
19 mars 1952
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall driva vetenskaplig konsultverksamhet, medicinskt-tekniskt utvecklingsarbete, läkartjänst, handel med läkemedel och hälsoprodukter samt värdepapper och fast egendom samt därmed förenlig verksamhet.
Address
Uddevallagatan 1
Phone
+4631191040
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 770 | 742 | 691 | 790 | 640 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 31 | 39 | 46 | 67 | 70 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 31 | 39 | 46 | 67 | 70 |
| Net financials | — | — | — | 64 | 140 |
| Profit before tax | 32 | 39 | 47 | 130 | 209 |
| Tax | −7 | −8 | −10 | −27 | −43 |
| Net profit | 25 | 31 | 37 | 103 | 166 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 788 | 3 777 | 3 830 | 3 970 | 4 104 |
| Equity | 336 | 367 | 404 | 507 | 674 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 452 | 3 410 | 3 426 | 3 462 | 3 430 |
| Total debt | 3 452 | 3 410 | 3 426 | 3 462 | 3 430 |
EBITDA margin
10.9%
This company
15.8%
Market median
-31% vs market
20202024
Equity ratio
16.4%
This company
38.2%
Market median
-57% vs market
20202024
Return on equity
24.6%
This company
18.4%
Market median
+34% vs market
20202024
Net profit margin
25.9%
This company
8.1%
Market median
+220% vs market
20202024
Asset turnover
0.16×
This company
1.12×
Market median
-86% vs market
20202024
Debt / equity
5.09×
This company
0.62×
Market median
-721% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JR Chief Executive Officer | Chief Executive Officer | 2022 |
RM | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
John Ouchterlony AB
Aktiebolaget Immuno Board members of Aktiebolaget Immuno also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| John Rolf Örjan Ouchterlony | Chief Executive Officer | 0 companies |
| Rolf Martin von Brömsen | Audit | 0 companies |
| Frank Bertel Ouchterlony | Deputy Board Member | 0 companies |